Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Abacavir
CAS: 136470-78-5
A nucleoside reverse transcriptase inhibitor (NRTI) and an anti-HIV drug used to treat HIV infection
API High Quality, Commercial Production
| Chemical Name | Abacavir |
| CAS Number | 136470-78-5 |
| CAT Number | RF-API62 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C14H18N6O |
| Molecular Weight | 286.33 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | Light Pink Powder |
| Assay | ≥99.0% (HPLC) |
| Melting Point | 122.0~126.0℃ |
| Specific Rotation | -12.0° ~ -15.0° |
| Water | ≤0.50% |
| Residue on Ingnition | ≤0.30% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Active Pharmaceutical Ingredient (API); anti-HIV |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Abacavir (CAS: 136470-78-5) with high quality.
Abacavir (Abacavir API) is a carbocyclic 2'-deoxyguanosine nucleoside reverse transcriptase inhibitor (NRTI) and an anti-HIV drug used to treat HIV infection. NRTIs work by blocking HIV reverse transcriptase, an HIV enzyme. Intracellular enzymes convert Abacavir to its active form, carbovir-triphosphate (CBV-TP), which then selectively inhibits HIV reverse transcriptase by incorporating into viral DNA. Abacavir is metabolized in the liver by uridine diphosphate glucuronyltransferase and alcohol dehydrogenase resulting in inactive glucuronide and carboxylate metabolites, respectively. This product is intended for the treatment of adults infected with human immunodeficiency virus (HIV).Three fixed components (abacavir, lamivudine, and zidovudine) are used in lieu of three monotherapies at similar doses.Abacavir, lamivudine, and zidovudine alone are recommended for 6-8 weeks at the beginning of treatment.The selection of this fixed combination should be based primarily on the expected benefits and risks associated with the three nucleoside analogues and not solely on the simple applicable criteria.
The major use of abacavir appears to be in combination with other nucleoside RT inhibitors. A fixed-combination product has recently been approved by the U.S. FDA consisting of 300 mg of ABC, 150 mg of 3TC, and 300 mg of ZDV (Trizivar). The combination has been shown to be superior to other combinations in reducing viral load as well as to show improvement in CD4 cell count. Abacavir is a nucleoside reverse transcriptase inhibitorNRTI that has been approved for use in combination therapiesfor the treatment of HIV and AIDS. Once in the tissues,it is metabolized by stepwise phosphorylation to themonophosphate, diphosphate, and triphosphate. Abacavir ishighly bioavailable (＞75%) and is effective by the oralroute. It penetrates the blood-brain barrier efficiently.